fda on tirzepatide Diabetes Drug - Gets Approval for Weight Loss Warning: Risks of Non-FDA Approved

This echoes the clinical practice already emerging with semaglutide and tirzepatide, where some prescribers step patients down after target weight is achieved

The excessive infiltration of SMs into synovia causes articular immune dysfunction, accelerates the progression of synovitis, and leads to osteoclast activation and ultimate bone erosion and joint destruction 7,8

10.1111/nmo.13454

There is a temptation, when facing the kind of demand disruption that GLP-1 represents, to treat it as existential and respond with wholesale portfolio transformation, but that response carries its own risks

GLP-1 Medications and Plastic Surgery: What You Need to Know Go Back At Straith Clinic, patient safety has always been at the center of everything we do